Objective-To investigate the ability of resolvin E1 (RvE1) to regulate adenosine diphosphate (ADP) activation of platelets via specific receptors because RvE1 reduces platelet aggregation with certain agonists, including ADP. Methods and Results-RvE1 is an eicosapentaenoic acid-derived specialized proresolving mediator generated during the resolution of acute inflammation. RvE1 exhibits potent organ-protective actions in vivo and acts on specific cell types, including platelets. RvE1, 0.1 to 100 nmol/L, incubated with platelets gave reduced ADP-stimulated P-selectin mobilization (IC 50 , approximately 1.6ϫ10 Ϫ12 mol/L) and polymerized actin content compared with control platelets. RvE1, 1 to 100 nmol/L, did not stimulate or block intracellular Ca 2ϩ mobilization. By using a new P2Y 12 -␤-arrestincoupled cell system, ADP-activated P2Y 12 with an EC 50 of 5ϫ10 Ϫ6 mol/L and RvE1 did not directly stimulate P2Y 12 or block the ADP-P2Y 12 signals. In this system, another eicosanoid, leukotriene E 4 (LTE 4 ) (EC 50 , 1.3ϫ10 Ϫ11 mol/L), dose dependently activated P2Y 12 . When recombinant P2Y 12 -expressing cells were transiently transfected with an RvE1 receptor, human ChemR23 (present on human platelets), with the addition of RvE1 (0.1-10.0 nmol/L), blocked ADP signals (IC 50 , approximately 1.6ϫ10 Ϫ11 mol/L) in P2Y 12 -ChemR23-expressing cells compared with mock transfections. Conclusion-RvE1's regulatory actions (ie, reducing ADP-stimulated P-selectin mobilization and actin polymerization) are human (h)ChemR23-dependent. Moreover, specific platelet actions of RvE1 selectively engaged with ADP-activated platelets that illuminate a new cellular mechanism and affect -3 eicosapentaenoic acid, which may contribute to both resolution of vascular inflammation and ADP-dependent platelet activation relevant in pathological cardiovascular events. (Arterioscler Thromb Vasc Biol. 2010;30:2005-2013.)
nent in several of the most prevalent human diseases in the developed world, including rheumatic diseases, diabetes mellitus, and cardiovascular diseases. [1] [2] [3] The identification of cellular and molecular mechanisms in resolution and inflammation and the roles of novel local chemical mediators demonstrate that resolution of acute inflammation is an active process, 4 -6 rather than a passive process, as previously believed. 2 It is becoming increasingly apparent that inflammatory diseases, such as periodontal disease, 7 atherosclerosis, 8 and Henoch-Schonlein purpura, 9 arise because of the failure in mounting endogenous resolution programs. 10 The timely resolution of acute inflammation is actively regulated by a new genus of endogenous mediators collectively called specialized proresolving mediators. This genus includes several families of structurally distinct, potent, and local-acting mediators (ie, lipoxins, resolvins, and protectins) that are biosynthesized from polyunsaturated essential fatty acids. 11, 12 A review 13 of results from several clinical studies demonstrates that diets rich in marine fish -3 polyunsaturated fatty acids reduce the risk of coronary events. The cellular mechanisms responsible for -3 fatty acid responses are of increasing general interest. 14 Circulating -3 fatty acids (eicosapentaenoic acid [EPA] and docosahexaenoic acid) rapidly appear in resolving inflammatory exudates carried by edema proteins in vivo, thus emphasizing the importance of circulating levels of -3 polyunsaturated fatty acids and their availability for conversion by exudates into resolvins and protectins. 15 Resolvins are enzymatic products of EPA and docosahexaenoic acid biosynthesized during the resolution phase of acute inflammation, initially isolated in self-limited murine exudates. 6, 16 They are agonists that exert both an antiinflammatory action (ie, they limit further neutrophil infiltration) and a proresolving action (ie, they stimulate nonphlogistic activation of macrophages). 11 Specifically, resolvin E1 (RvE1), a member of the E series of resolvins, is biosynthe-sized from EPA and was first identified in vivo during the resolution phase of inflammation from exudates. 6 The levels of RvE1 monitored in plasma from healthy human volunteers taking fish oil ranged from 0.1 to 0.4 ng/mL. 17 This is commensurate with RvE1 bioactions evoked in the picomolar to nanomolar per liter range.
With isolated human cells, RvE1 is produced by hypoxiaactivated human endothelial cells that convert EPA to an 18R-hydroxy-containing intermediate via aspirin-acetylated cyclooxygenase 2. 6 Also, 18R-hydroxy-eicosapentanoic acid (18R-HEPE) is produced by microbial P450. 18 Once formed, 18R-HEPE is rapidly transformed by activated leukocytes to a 5 (6)-epoxide-18R-hydroxy-containing intermediate, in which 5-lipoxygenase performs consecutive steps. 19 RvE1 complete stereochemistry is established (5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid) and is a stereoselective agonist that interacts with at least 2 identified Gprotein-coupled receptors (GPCRs): ChemR23 17 and leukotriene B 4 receptor (BLT)-1. 20 These findings were reviewed by Shimizu. 21 RvE1 possesses potent anti-inflammatory and proresolving actions in animal models of disease and acts on a wide range of cell types, 11 including leukocytes and platelets in whole blood. 22 Unlike BLT1, which is present on platelets, 23 ChemR23 was recently identified on megakaryocytes and the surface of human platelets. 22 RvE1 has stereoselective antiaggregatory actions with human platelets 22 ; at concentrations as low as 1 nmol/L, RvE1 blocks adenosine diphosphate (ADP), 10 mol/ L-stimulated platelet aggregation and thromboxane generation. 22 The platelet actions of ADP are of particular interest because it is well appreciated as an important local mediator of hemostasis and thrombosis and when aberrantly regulated platelets contribute to the pathogenesis of cardiovascular diseases. 24, 25 On platelets, ADP specifically binds and activates 2 G-proteincoupled receptors, P2Y 1 and P2Y 12 . Transduction of the ADP signal involves inhibition of adenyl cyclase (via P2Y 12 ) and a concomitant transient increase of intracellular Ca 2ϩ (via P2Y 1 ). 25 Further downstream signaling results in robust shape changes, inside-out activation of platelet receptors (eg, glyocoprotein [GP]IIbIIIa), and granule secretion. 25 Antiplatelet therapies targeted at blocking purinergic receptor signaling, specifically P2Y 12 antagonists, are the focal point of platelet therapeutics 26 and are among the most widely used pharmacotherapy in cardiovascular diseases. 27, 28 Because we found that RvE1 has potent and stereoselective actions in blocking ADP-stimulated platelet aggregation, 22 we examined RvE1's actions in ADP-activated platelets. Herein, we report that RvE1 regulates ADP-stimulated P-selectin surface mobilization and actin polymerization and that RvE1 counterregulates P2Y 12 signaling in a receptordependant (ChemR23) manner in transfected cells. These findings may have implications for dietary EPA supplementation for the maintenance of vascular homeostasis and the resolution of acute inflammation.
Methods

Antibodies, Reagents, and Cell Lines
Phycoerythrin (PE)-conjugated mouse anti-human CD62P and antihuman fluorescein isothiocyanate (FITC)-CD41 were from BD Biosciences, Rockville, Md. Mouse anti-human ChemR23 (clone 84939) was purchased from R&D (Minneapolis, Minn). Goat antimouse IgG3 was purchased from Pharmingen (San Jose, Calif).
19-para-Fluorophenoxy-RvE1 (an RvE1 analogue) 29, 30 was prepared by total organic synthesis, as done previously (N. Petasis, PhD, in the Specialized Center for Oral Inflammation and Resolution [Charles N. Serhan P50 DE016191]). 17 Prostaglandin E1 (PGE 1 ) and RvE1 were purchased (Cayman, Ann Arbor, Mich). Physical and biological properties were matched to published RvE1. The structural integrity and concentration of RvE1 were monitored using UV tandem liquid chromatography-mass spectroscopy-mass spectroscopy. 6, 17 ADP was obtained commercially (Sigma Chemical, St Louis, Mo), as were permeabilization buffer (eBioscience, San Diego, Calif), a fura-2 fluorescent probe (Invitrogen, Carlsbad, Calif), and FITC-phalloidin (Sigma). Megakaryoblast (MEG)-01 and Chinese hamster ovary (CHO) cells were purchased from American Type Culture Collection, Manassas, Va. pcDNA3-hChemR23 CHO cells were prepared as done previously. 31 A sensiscript reverse transcription kit and a Hotstar Taq polymerase master mix kit were purchased (Qiagen, Valencia, Calif), as were fugene transfection reagents (Roche Diagnostics Corporation, Indianapolis, Ind).
Primers
The following primers were purchased from Invitrogen: human ChemR23, 5Ј-ATGAGAATGGAGGATGAAGA-3Ј and 5Ј-TCAAA-GCATGCCGGTCTCC-3Ј; human P2Y 12 , 5ЈCAAGCCGTCGAC-AACCTCACCTC-3Ј and 5Ј-TCTCGGCTGCCTGTTGGTCAGAA-3Ј; human P2Y 1 , 5Ј-GTGCTGGTGTGGCTATTGTGGT-3Ј and 5Ј-GGCTTGTATCTCCATTCTGCTTGA-3Ј; human BLT1, 5Ј-TATG-TCTGCGGAGTCAGCATCTACGC-3Ј and 5Ј-CCTGTAGCCGAC-GCCCTATGTCCG-3Ј; and GAPDH, 5Ј-GACCACAGTCCATGAC-ATCACT-3Ј and 5Ј-TCCACCACCCTGTTGCTGTAG-3Ј.
Platelet P-Selectin
Platelet-rich plasma (PRP) was isolated from healthy human whole blood donors who had not taken nonsteroidal anti-inflammatory drugs for 14 days before donation and was anticoagulated with acid-citrate-dextrose (1:10), as done previously. 22 In brief, synthetic RvE1 or 19-para-fluorophenoxy-RvE1, 0.001 to 100 nmol/L, was incubated in PRP for 15 minutes at 37°C. Platelets were then incubated with ADP, 10 mol/L, for 3 minutes (37°C at pH 7.45) with intermittent mixing. Incubations were discontinued by adding 6% formalin (15 minutes at 4°C). Platelets were stained with either anti-mouse IgG, PE-mouse anti-human CD62P (1:100 dilution), or FITC-anti-human CD41 (1:100 dilution) for 20 minutes at 4°C. Surface expression was monitored using fluorescent activated cell sorting (FACSort) (Becton Dickinson, Franklin Lakes, NJ) and computer software (Cellquest). Platelets were identified by positive CD41 and CD62P staining compared with appropriate IgG control.
ADP-Stimulated Morphology Changes and Intracellular Ca 2؉ Mobilization
RvE1, 100 nmol/L, and/or vehicle was added to PRP at 37°C with gentle agitation 15 minutes before the addition of ADP, 10 mol/L. ADP incubations were performed for 0, 15, 30, and 60 seconds at 4°C in the presence of vehicle or RvE1. The addition of cold 6% formalin stopped the incubations, and cells were exposed to FITCphalloidin (1:100) for 1 hour at 4°C. Increases in positive FITC fluorescence compared with vehicle were quantified (via flow cytometry) as polymerized actin. Intracellular Ca 2ϩ mobilization was assessed by changes in fura-2, 1 mmol/L, fluorescence and analyzed via FlexStationIII (Institute of Chemistry and Cell Biology-Longwood, Harvard Medical Screening Facility).
Human Megakaryocyte Cell Line (MEG-01)
The MEG-01 cell line (American Type Culture Collection, CRL-2021) 32 was cultured in RPMI medium 1640 supplemented with 10% FBS at 37°C. To assess the expression of ChemR23, BLT1, P2Y 12 , and P2Y 1 in MEG-01 cells, PCR was performed. To detect the surface expression of ChemR23 and BLT1, 1ϫ10 6 cells were stained with anti-human ChemR23, anti-human BLT1, or goat anti-mouse IgG control and analyzed using flow cytometry with computer software (CellQuest). Changes in actin polymerization of MEG-01 (1ϫ10 5 cells per treatment) were monitored as done previously. Experiments were performed using cells that had undergone no more than 10 passages.
Actin Polymerization in CHO Cells Stably Expressing Human ChemR23
CHO cells stably expressing human ChemR23 or mock (pcDNA3) were prepared 31 and cultured in Ham's F12, 10% FBS, and G418, 800 g/mL. Cells were plated (1ϫ10 5 cells per well) in a 96-well plate and incubated with ADP, 10 mol/L, 33 or RvE1, 10 nmol/L, plus ADP, 10 mol/L, for 60 minutes 34 at 37°C. FITC-phalloidin was used to monitor changes in actin modification, and fluorescence was acquired using a plate reader (EnVision; ICCB-Longwood, Harvard Medical Screening Facility).
P2Y 12 ␤-Arrestin System
PathHunter CHO-K1 cells overexpressing human P2Y 12 were cultured 35 and obtained from DiscoverX (Fremont, Calif). 36 CHO-P2Y 12 ␤-arrestin cells were cultured in Ham's F12 media supplemented with G418, 800 g/mL; hygromycin, 300 g/mL; and 10% FBS at 37°C. Cells were incubated (1ϫ10 5 cells per well) in 96-well plates for 24 hours at 37°C. Incubations were performed in Hams F12 media (without FBS or antibiotics). ADP, 10 nmol/L to 100 mol/L; RvE1, 0.1 to 100 nmol/L; or RvE1 plus ADP were added for 60 minutes, at 37°C. P2Y 12 activation was determined by chemiluminescence (PathHunter energy fragment complementation detection kit) 36 using a luminometer (EnVision; ICCB-Longwood, Harvard Medical Screening Facility). Transient transfection of human ChemR23 or pcDNA3 (as a mock control) was performed for 48 hours, using transfection regents (FuGENE). Flow cytometry was used to validate surface expression of hChemR23.
The significance of differences between groups was evaluated using the 2-tailed t test or ANOVA with Bonferroni post testing. PϽ0.05 was considered statistically significant (GraphPad software).
Results
RvE1 Counters ADP-Dependent Platelet Activation
ADP is released from granules within activated platelets during the secondary wave of platelet aggregation that, in turn, activates neighboring platelets and/or leukocytes. 25 To determine whether RvE1 regulates ADP-dependent platelet activation, human PRP was incubated with RvE1, 0.001 to 100 nmol/L, for 15 minutes, followed by ADP, 10 mmol/L, for 3 minutes; and surface P-selectin was monitored. The appearance of P-selectin on the surface of platelets is a sensitive marker of platelet activation. RvE1 is more potent than its precursor, EPA, and limited ADP-stimulated P-selectin surface mobilization, giving an approximately 30% reduction at 1 nmol/L ( Figure 1A ). In comparison, an RvE1 stable analogue, 19-para-fluorophenoxy-RvE1, 29, 30 appeared to be equipotent ( Figure 1B) to RvE1. Representative histograms in Figure 1C demonstrate that neither RvE1 nor its analogue, 19-para-fluorophenoxy-RvE1 alone, 0.001 to 100 nmol/L, increased P-selectin surface mobilization ( Figure 1C panel i and ii, respectively). In addition, we confirmed the surface expression of ChemR23 on CD41 ϩ human platelets ( Figure 1C panel v) and found that 19-para-fluorophenoxy-RvE1 reduced ADP-stimulated platelet aggregation ( Figure  1C panel vi). Next, we compared RvE1's actions with ADP-stimulated P-selectin mobilization with that of PGE 1 , 0.01 to 100 nmol/L, a prostanoid that blocks platelet activation via stimulation of cAMP. 25 RvE1, 0.1 and 1.0 nmol/L, significantly reduced ADP-stimulated P-selectin mobilization when compared on a molar basis with PGE 1 (Figure 1D) . At low doses, RvE1 appeared more potent that PGE 1 reduction of P-selectin mobilization, whereas at a higher concentration, PGE 1 gave stronger maximal inhibition.
RvE1 Blocks Platelet Actin Polymerization
On activation, platelets undergo robust shape changes. 25 Therefore, we assessed whether RvE1 modulates the actin cytoskeleton on ADP-dependent stimulation. When compared with ADP, 10 mol/L, RvE1 alone, 100 nmol/L, did not stimulate actin polymerization in PRP (Figure 2A ). When administered 15 minutes before ADP, RvE1, 100 nmol/L, significantly blocked ADP-stimulated actin polymerization by 40.5Ϯ3.6% and 50.0Ϯ6.7% at 30 and 60 seconds, respectively ( Figure 2B) . These results indicate that RvE1 dampens platelet responses by blocking the potentiation of ADPstimulated morphological changes.
RvE1's Actions on Human Platelets Are Not a Consequence of Intracellular Ca 2؉ Mobilization
ADP stimulation via P2Y 1 releases intracellular Ca 2ϩ stores, which further enhances platelet activation. 25 RvE1 itself neither stimulated Ca 2ϩ mobilization ( Figure 2C ) nor blocked ADP-stimulated intracellular Ca 2ϩ release in human PRP ( Figure 2D ). To assess whether RvE1 blocks intracellular Ca 2ϩ mobilization from other platelet agonists, the TXA 2 receptor agonist U46619, 500 mol/L, and thrombin, 1 U/mL, were each tested (nϭ3). RvE1, 1 to 100 nmol/L, did not block either U46619-or thrombin-stimulated Ca 2ϩ mobilization (nϭ3, data not shown). These results suggest that RvE1's actions on platelet activation are not a consequence of signaling events via P2Y 1 that lead to intracellular Ca 2ϩ mobilization.
RvE1 Recombinant Human ChemR23 Interactions Are Required to Reduce ADP-Stimulated Actin Polymerization
Because an RvE1 receptor ChemR23 17 was recently identified on human platelets, 22 we tested whether RvE1 actions in regulation of ADP responses were mediated by ChemR23. On ADP stimulation, actin is polymerized as indicated by punctate staining of FITC-phalloidin ( Figure 3A and B) . ADP-stimulated actin polymerization reached a maximal response at 30 seconds, whereas RvE1, 100 nmol/L, alone did not ( Figure 3B ). When given 15 minutes before ADP, RvE1 effectively reduced ADP-stimulated actin, reaching a maximal inhibition at 60 seconds ( Figure 3C ). The MEG-01 (human megakaryoblast) cell line was selected because it expresses ChemR23, P2Y 12 , and P2Y 1 , but not BLT1 ( Figure  3D and E). This was useful because RvE1 can also interact with BLT1 20 present on human neutrophils. Because CHO cells express P2Y receptors, 33 we further examined and quantitated ChemR23-dependent counterregulation of ADP activation; we prepared CHO cells that stably overexpressed recombinant human ChemR23 (CHO-hChemR23). RvE1, 10 nmol/L, significantly (PϽ0.01) reduced ADP, 10 mol/L, stimulated actin polymerization in CHO-hChemR23-expressing cells but not in CHO-mock cells ( Figure 3F ).
RvE1 Blocks ADP-Stimulated P2Y 12 Activation
P2Y 12 , coupled to G␣, is the ADP receptor on platelets that is primarily responsible for blocking adenyl cyclase and cAMP accumulation and potentiating P2Y 1 (a platelet ADP receptor coupled to Gq and intracellular Ca 2ϩ mobilization) signaling events. 25 Because RvE1 blocked the potentiation of platelet actin polymerization (Figure 2A and B) without evoking mobilization of intracellular Ca 2ϩ ( Figure 2C and D), we investigated P2Y 12 signaling. To monitor ligand receptor interactions, we used a new GPCR-␤-arrestin-coupled system that consisted of CHO cells stably overexpressing ␤-arrestin and recombinant human P2Y 12 (CHO-P2Y 12 ). ADP (EC 50 , 5ϫ10 Ϫ6 mol/L) dose dependently activated CHO-P2Y 12 ␤-arrestin cells, whereas RvE1 did not ( Figure  4A ). In addition, RvE1, 10 Ϫ10 to 10 Ϫ6 mol/L, did not block ADP activation of P2Y 12 , suggesting that RvE1 did not interact with P2Y 12 directly ( Figure 4B ). In light of the recent findings that LTE 4 may be a ligand for P2Y 12 , 37 we sought to investigate the LTE 4 interaction with P2Y 12 using this cell system. We directly compared LTE 4 with leukotriene D 4 (LTD 4 ) at equiconcentrations, 10 Ϫ12 to 10 Ϫ8 mol/L. LTE 4 (EC 50 , 1.3ϫ10 Ϫ11 mol/L) dose dependently activated P2Y 12 , whereas LTD 4 at the same concentration range was ineffective ( Figure 4C ). In addition, LTE 4 , 10 Ϫ10 to 10 Ϫ8 mol/L, blocked ADP activation of P2Y 12 in this system ( Figure 4D ), suggesting that LTE 4 directly interacts with P2Y 12 .
To further elucidate whether RvE1's counterregulatory action is via ChemR23, we transiently transfected recombinant human ChemR23 (P2Y 12 -ChemR23) or pcDNA3 (P2Y 12 -Mock) as a mock control into the CHO-P2Y 12 ␤-arrestin cells. Transfection was confirmed by assessing surface expression of FITC-anti-human-ChemR23 ( Figure  5A ). RvE1, 10 Ϫ10 to 10 Ϫ8 mol/L, when added 15 minutes before ADP, significantly blocked P2Y 12 activation in the P2Y 12 -ChemR23 cells compared with the P2Y 12 -Mock-transfected cells. Lower doses of RvE1, 10 Ϫ11 mol/L, did not block ADP-stimulated P2Y 12 activation in P2Y 12 -ChemR23 cells compared with P2Y 12 -Mock (data not shown). In contrast, RvE1, 10 Ϫ10 to 10 Ϫ8 mol/L, did not block LTE 4 , 10Ϫ 9 mol/L, activation of P2Y 12 in P2Y 12 -ChemR23 or P2Y 12 -Mock cells (data not shown), suggesting that RvE1 and LTE 4 each interact with P2Y 12 via different mechanisms.
Discussion
Results from several clinical studies demonstrate that -3 polyunsaturated fatty acids, such as EPA and docosahexaenoic acid, have beneficial actions in diseases in which platelets play central pathogenic roles, such as cardiovascular disease and stroke. 13 In this article, we report the potent actions of EPA-derived RvE1 on human platelets. EPA is not converted to RvE1 by isolated platelets. EPA is biosynthesized in the vasculature and produced in vivo within plasma/ whole blood 17 ; thus, it quieces the activation of platelets and leukocytes. 22 For example, RvE1 regulates ADP-and U46619-stimulated platelet aggregation but not collagenstimulated platelet aggregation in an agonist-specific and stereoselective manner. 22 Herein, we report that RvE1 downregulates (1) ADP-stimulated platelet activation by reducing P-selectin mobilization and the potentiation of platelet actin polymerization, (2) without altering Ca 2ϩ mobilization, and (3) by P2Y 12 -ADP signaling via the RvE1 receptor, ChemR23. In A, images are representative of 3 experiments (B and C); data are given as the meanϮSEM. D, Representative gel of P2Y 12 (P2Y 12 ), P2Y 1 (P2Y 1 ), ChemR23, and BLT1 expression. All products were 0.3 kb, with the exception of full-length human ChemR23, which was 1 kb. E, MEG-01 surface expression of ChemR23 (left, solid line) or BLT1 are shown compared with their respective isotype matched controls (shaded). F, Mock pcDNA3 or hChemR23 was transiently transfected into CHO cells using lipofectamine 2000 for 48 hours at 37°C. CHO-Mock or CHO-hChemR23 cells (1ϫ10 5 ) were stimulated with RvE1, 10 nmol/L, 15 minutes before ADP, 10 mol/L, stimulation (60 minutes at 37°C). FITC-phalloidin fluorescence was assessed via a plate reader (EnVision) and computer software. Data are given as the meanϮSEM (nϭ3). *PϽ0.01. P-selectin is an important modulator of coagulation and inflammation because of its role in cell-cell adhesion with platelets, leukocytes, and the vascular endothelium. 1, 25 The present results demonstrate that RvE1 and its metabolically stable analogue 19-para-fluorophenoxy-RvE1 reduced ADPstimulated P-selectin surface mobilization (Figure 1 ). In addition, we performed aggregation studies and found that 19-para-fluorphenoxy-RvE1, 10 nmol/L, reduced ADPstimulated platelet aggregation ( Figure 1C ) comparable to RvE1. 22 RvE1's biologically inactive isomer, D6,14trans-RvE1, did not reduce ADP-stimulated platelet aggregation. 22 These results underscore that RvE1's stereoselective actions and its ability as a local mediator may control platelet-platelet and platelet-leukocyte aggregate formation and their interactions with activated endothelium. These findings are in agreement with recent results, 22 in which RvE1 reduces surface expression of selectins and integrins on neutrophils and monocytes in human whole blood and promotes detachment of leukocytes from endothelium in microcirculation.
Platelets play a pivotal role in circulation through the preservation of vascular integrity and the prevention of hemorrhage after injury. 25 Although the formation of a thrombus (ie, platelet-platelet and platelet-leukocyte aggregates) is a protective mechanism for wound healing, excessive thrombus formation may lead to pathological events, such as acute myocardial infarction or stroke. 27 The capacity of platelets to form thrombi is dependent on their ability to aggregate, which, at the molecular level, is in part because of the activation of selectins (ie, P-selectin) and integrins, such as GPIIbIIIa. Inside-out activation of GPIIbIIIa from downstream ADP signaling occurs. On activation, GPIIbIIIa is able to bind its ligand (fibrinogen), stimulating outside-in signal-ing and, thus, further activation of the platelet and stabilization of the clot. 25 At higher concentrations, we found that 100-nmol/L RvE1 reduces fibrinogen binding to platelets, 38 which points to a potential role for local RvE1 in regulating formation of thrombi and platelet-leukocyte aggregates, also observed with RvE1 added to whole blood. 22 These results are consistent with P-selectin regulation by ADP (Figure 1 ), in which RvE1 appeared to quiesce activation of platelets and subsequent thrombus formation and dampen plateletleukocyte interactions. 22 Complete abolition of platelet responses could lead to excessive bleeding, a common adverse effect of most current antiplatelet therapeutics. 26 Thus, RvE1 did not completely block ADP-stimulated platelet activation, underscoring its potential to modulate platelet responses to ADP for the maintenance of vascular homeostasis.
Platelets undergo rapid morphological changes on activation by a range of agonists, including thrombin, thromboxane A 2 , and ADP. 25 RvE1 does not regulate either thrombin-or collageninitiated 22 platelet responses, suggesting that RvE1's actions on platelets are highly selective toward regulating ADP's local vascular roles. When platelets are initially stimulated, the first event is a rearrangement of the cytoskeletal proteins (actin and myosin); and the normally disc-shaped cells change into spheres with filopodia. 25, 39 Actin is polymerized on ADP stimulation, 25, 39 primarily via engagement of P2Y 1 . 40 Results for P2Y 1deficient mice demonstrated that P2Y 1 accounts for the ability of ADP to induce changes in morphological features and the large intraplatelet Ca 2ϩ mobilization that precedes aggregation. 41, 42 The role of P2Y 12 in platelet shape change is to potentiate the actions from P2Y 1 signaling. 25, 43 In the present experiments, we found that RvE1 reduces the potentiation of ADP-stimulated actin polymerization in human platelets (Figure 2 ). On its own, Figure 4 . RvE1 counterregulates P2Y 12 signaling. ADP, 10 Ϫ10 to 10 Ϫ4 mol/L, added to CHO-P2Y 12 (1ϫ10 5 cells per well); RvE1, 10 Ϫ10 to 10 Ϫ6 mol/L; LTE 4 , 10 Ϫ12 to 10 Ϫ8 mol/L; or LTD 4 , 10 Ϫ12 to 10 Ϫ8 mol/L, was added for 60 minutes at 37°C. All incubations were stopped with lysis buffer containing emerald substrate reagent for 60 minutes at 21°C. EC 50 values were determined by curve fit analysis using computer software (GraphPad). A, ADP and RvE1 dose response. Data are given as the meanϮSEM (nϭ5). B, RvE1, 10 Ϫ10 to 10 Ϫ7 mol/L; when added simultaneously with ADP. C, LTE 4 and LTD 4 dose response. Data are given as the meanϮSEM (nϭ6). D, LTE 4 , 10 Ϫ9 to 10 Ϫ8 mol/L, followed by ADP, 10 Ϫ5 mol/L. Data are given as the meanϮSEM (nϭ3). *PϽ0.05. RLU indicates relative luminescent units.
RvE1 did not stimulate actin polymerization (Figure 2 ), indicating that RvE1 is not a classic platelet agonist and that its actions appear to be selective in counterregulating the procoagulatory agonist, ADP. P2Y 12 signaling completes platelet aggregation initiated by P2Y 1 and plays a central role in amplifying aggregation to other known agonists, such as thromboxane A 2 . 25, 26 RvE1 reduced ADP-stimulated thromboxane generation, 22 which is consistent with RvE1 blocking P2Y 12 -mediated signaling events. Recently, it was shown that the P2Y 1 -mediated Ca 2ϩ flux is unchanged in P2Y 12 Ϫ/Ϫ mice, demonstrating that P2Y 12 does not participate in the Ca 2ϩ response and that there is no apparent compensatory increase of P2Y 1 function in the knockout mice. 44 Also, P2Y 12 Ϫ/Ϫ mice have a diminished aggregation response to ADP. 44 RvE1's ability to quiesce ADP-stimulated aggregation 22 and actin polymerization content, without modulating intracellular Ca 2ϩ mobilization (Figure 2 ), is consistent with results from platelets congenitally lacking P2Y 12 45 and from P2Y 12 knockout mice. 44 P2Y 12 is desensitized via G-protein receptor kinases and ␤-arrestin in human platelets. 46 When ADP binds to P2Y 12 , G-protein receptor kinases are activated, 46 phosphorylating the c-terminus of P2Y 12 . On phosphorylation, ␤-arrestin is recruited and physically associates with the activated c-terminal region, which leads to the internalization and desensitization of the GPCR, a process known as homologous receptor desensitization. 47 P2Y 1 signaling in human platelets is desensitized by other mechanisms not associated with ␤-arrestin. 46 Thus, we used a recombinant P2Y 12 -␤-arrestincoupled system to evaluate the following: (1) RvE1's regulatory actions and (2) members of the leukotriene series of mediators known to be important in slow-reacting substances of anaphylaxis on P2Y 12 signaling because LTE 4 was identified as a putative ligand. 37 RvE1 did not directly activate P2Y 12 ( Figure  4A and B) . In contrast, LTE 4 directly activated recombinant P2Y 12 (Figure 4C and D) , a finding consistent with recent reports 48, 49 suggesting that leukotriene E 4 (LTE 4 ), once considered inactive in slow-reacting substances of anaphylaxis metabolite, 48 may be relevant in allergic reactions in humans.
In addition to nucleotides, eicosanoids are also mediators of thrombosis and vascular homeostasis. 24 Thromboxane A 2 stimulates platelets, and prostacyclin counteracts platelet activation. 50 Cysteinyl leukotriene (CysLT) were identified at sites of thrombus formation and in atheroma plaques in vivo. 51 Yet, the actions of CysLTs on platelet function are insufficiently understood. Recently, LTE 4 has been reported to activate mast cells in a P2Y 12 -dependent fashion. 49 Therefore, the present experiments with the P2Y 12 -b-arrestin system that LTE 4 is an activating ligand for P2Y 12 and an effective competitor of ADP activation of this receptor.
Because RvE1 did not directly activate or block ADPstimulated recombinant P2Y 12 activation ( Figure 5A and B) , we sought evidence for whether the expression of recombinant human ChemR23 may mediate RvE1's counterregulatory actions in ADP-P2Y 12 signaling. When recombinant human ChemR23, 1 of the RvE1 GPCRs, was coexpressed on this cell system, RvE1 significantly blocked P2Y 12 activation in the P2Y 12 -ChemR23 compared with P2Y 12 -Mock. In this recombinant system, it appears that RvE1 activation of ChemR23 (RvE1-ChemR23) is a threshold-dependent response, likely a phosphorylation event that blocks ADP-P2Y 12 signaling to action. These findings suggest that RvE1 counterregulates P2Y 12 signaling in a ChemR23-dependent manner ( Figure 5B ). Also, these results provide the first example that resolvins may interact not only with their cognate receptor but also with other ligandactivated GPCR-mediated signals.
A classic example of endogenous ligand-GPCR-mediated counterregulation in the vasculature is the interaction between prostacyclin (IP) and thromboxane (TP␣) receptors. 24, 50, 52 To Figure 5 . RvE1 regulates P2Y 12 signaling in a ChemR23dependant manner. A and B, CHO-hP2Y 12 ␤-arrestin cells were transiently transected with mock-pcDNA3 or hChemR23 using transfection reagent (FuGene) for 48 hours at 37°C. Cells were plated (1ϫ10 5 cells per well); and ADP, 10 Ϫ5 mol/L, or ADP plus RvE1, 10 Ϫ10 to 10 Ϫ8 mol/L, were incubated for 60 minutes at 37°C. A, Human ChemR23 transient transfection was monitored using flow cytometry. Histograms are representative of 4 experiments. B, Inhibition of P2Y 12 by RvE1 was monitored in mock-pcDNA3 or hChemR23. Data are given as the meanϮSEM (nϭ4). *PϽ0.03, 2-way ANOVA with Bonferroni posttesting. C, Proposed scheme for RvE1 actions on human platelets. The "Discussion" section provides further details. limit TXA 2 activation, IP can form dimers with TP␣. 53 Thus, it is also feasible that in acute inflammation, agonists of resolution of inflammation and regulators of hemostasis, such as RvE1, act in concert with other receptors to control the magnitude of platelet activation in the local environment.
In summation, ADP is an agonist of cardiovascular events; an improved understanding of the mechanisms by which platelets become inactivated is of immense interest. 28 RvE1 reduces ADP-stimulated human platelet aggregation 22 ; in the present study, we document that RvE1 counterregulates ADP-stimulated P-selectin surface mobilization and the potentiation of actin polymerization in a Ca 2ϩ -independent manner. Together, these findings suggest that RvE1 actions are counterregulating P2Y 12 signaling in human platelets, as illustrated in Figure 5C . In support of this model, results from the GPCR-␤-arrestin-coupled recombinant system indicate that RvE1's counterregulation of P2Y 12 is RvE1 receptor (ChemR23) dependent. These findings can provide novel approaches for platelet therapies and explain, in part, the actions of dietary EPA via local RvE1 production and platelet interactions, which affect cardiovascular diseases and timely return of homeostasis.
